Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between… Read More
– Under terms of the agreement with Axovant signed in June 2018, this has triggered a $15 million milestone to Oxford Biomedica Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, notes that Axovant Gene Therapies Ltd. (NASDAQ: AXGT) has announced the… Read More
Oxford, UK – 26 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Kymriah® (tisagenlecleucel) for the treatment of two distinct indications – CD19-positive relapsed or refractory (r/r) B-cell… Read More
Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group today announces preliminary results for the year ended 31 December 2018. FINANCIAL HIGHLIGHTS • Gross income increased by 72%… Read More
Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group today announces preliminary results for the year ended 31 December 2018. FINANCIAL HIGHLIGHTS • Gross income increased by 72%… Read More
Oxford, UK – 12 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with Microsoft Research to improve the yield and quality of next generation gene therapy vectors using the cloud and machine learning. Read More
Oxford, UK – 11 March 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes Axovant’s update on the Phase 2 SUNRISE-PD study of AXO-Lenti-PD. Axovant reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing… Read More
London, UK – 8 February 2019: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, will be announcing its Preliminary Results for the year ended 31 December 2018 on Thursday 14 March 2019. A briefing for analysts will be held at 12:00pm GMT… Read More
Oxford, UK – 7 February 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, has been informed that as part of a company-wide portfolio review, Sanofi intends to seek a new partner for Oxford Biomedica’s outlicensed ophthalmology gene therapies, SAR422459 for Stargardt… Read More
Oxford, UK – 06 December 2018: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, notes an announcement today by Axovant Sciences regarding feedback from a face-to-face pre-IND meeting with the U.S. Food and Drug Administration (FDA) concerning AXO-Lenti-PD for patients with Parkinson’s… Read More
Oxford, UK – 01 December 2018: Oxford Biomedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis on the longer-term analyses of both the ELIANA and JULIET pivotal trials in children and young adult patients with relapsed or refractory… Read More
Oxford, UK – 23 November 2018: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces the formation of a new digital framework initiative to streamline the production of next-generation medicines. Oxford Biomedica will invest a total of £4 million, supported by… Read More